Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the develo...
Amgen (NASDAQ:AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...
GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: ...
DANNCE.AI raised $2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The L...
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist&...
Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, announced that the first patient has been successfully dosed in the Phas...
The Association of American Physicians and Surgeons Educational Foundation (“AAPS”) filed its reply in support of adding allegations against ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zan...
" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...
Eli Lilly and Company (NYSE: LLY) announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhi...
© 2025 Biopharma Boardroom. All Rights Reserved.
